Cardiovascular Diseases & Diagnosis

Stefan Naydenov Naydenov

Publications

• Research Article
  Lipid-Lowering Potency and Tolerability of Generic Rosuvastatin in Bulgarian Patients with High and Very High Risk
  Author(s): Stefan Naydenov Naydenov, Nikolay Margaritov Runev, Emil Ivanov Manov, Rabhat Ahmed Shabani and Temenuga Ivanova DonovaStefan Naydenov Naydenov, Nikolay Margaritov Runev, Emil Ivanov Manov, Rabhat Ahmed Shabani and Temenuga Ivanova Donova
  
  Background: Statins are a class of drugs for treatment of dyslipidemias, but they are also known to significantly reduce the cardiovascular morbidity and mortality in patients at high cardiovascular risk. The objective of our study was to assess the lipid-lowering potency and tolerability of generic rosuvastatin ROSWERA®, prescribed to patients at high and very high cardiovascular risk, with or without hypercholesterolemia. Methods: Forty-five consecutive patients (24 females, 53.3%), mean age 62 years were included in this prospective study. ROSWERA® was prescribed 10 to 20 mg once in the evening for primary prevention of high-risk patients or secondary prevention of patients with an overt cardiovascular disease. Levels of total cholesterol, LDLcholesterol, HDL-cholesterol, triglycerides, transaminases and creatine kinase were exami.. Read More»
  DOI: 10.4172/2329-9517.1000162

  Abstract PDF